MEDSCI's subsidiary wins bid for a large real-world research project "Gout Smart Management Program" from a Chinese pharmaceutical company
I'm PortAI, I can summarize articles.
MEDSCI's subsidiary, Shanghai MEDSCI Pharmaceutical Technology Co., Ltd., has won the bid for a large real-world research project titled "Gout Smart Management Program" from a Chinese pharmaceutical company, with a project amount of approximately 21 million yuan. The study will evaluate the efficacy and safety of IL-1β monoclonal antibody treatment in gout patients, combining prospective and retrospective observations. MEDSCI is committed to improving healthcare quality through its internet doctor platform and big data technology
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments